Encrypted login | home

Program Information

Outcomes of Hypofractionated Treatments - Initial Results of the WGSBRT

X Li
no image available
P Lee
no image available
N Ohri
no image available
M Joiner
no image available
F Kong
no image available
A Jackson

X Li1*, P Lee2*, N Ohri3*, M Joiner4*, F Kong5*, A Jackson6*, (1) Medical College of Wisconsin, Milwaukee, WI, (2) UCLA, Los Angeles, CA, (3) Albert Einstein College of Medicine, Bronx, NY, (4) Wayne State University, Detroit, MI, (5) Georgia Regents University, Augusta, GA, (6) Mem Sloan-Kettering Cancer Ctr, New York, NY


TU-A-BRD-1 Tuesday 7:30AM - 9:30AM Room: Ballroom D

Stereotactic Body Radiation Therapy (SBRT) has emerged in recent decades as a treatment paradigm that is becoming increasingly important in clinical practice. Clinical outcomes data are rapidly accumulating. Although published relations between outcomes and dose distributions are still sparse, the field has progressed to the point where evidence-based normal tissue dose-volume constraints, prescription strategies, and Tumor Control Probability (TCP) and Normal Tissue Complication Probability (NTCP) models can be developed.

The Working Group on SBRT (WGSBRT), under the Biological Effects Subcommittee of AAPM, is a group of physicists and physicians working in the area of SBRT. It is currently performing critical literature reviews to extract and synthesize usable data and to develop guidelines and models to aid with safe and effective treatment. The group is investigating clinically relevant findings from SBRT in six anatomical regions: Cranial, Head and Neck, Thoracic, Abdominal, Pelvic, and Spinal.

In this session of AAPM 2014, interim results are presented on TCP for lung and liver, NTCP for thoracic organs, and radiobiological foundations:

• Lung TCP: Detailed modeling of TCP data from 118 published studies on early stage lung SBRT investigates dose response and hypothesized mechanisms to explain the improved outcomes of SBRT. This is presented from the perspective of a physicist, a physician, and a radiobiologist.
• Liver TCP: For primary and metastatic liver tumors, individual patient data were extracted from published reports to examine the effects of biologically effective dose on local control.
• Thoracic NTCP: Clinically significant SBRT toxicity of lung, rib / chest wall and other structures are evaluated and compared among published clinical data, in terms of risk, risk factors, and safe practice.
• Improving the clinical utility of published toxicity reports from SBRT and Hypofractionated treatments. What do we want, and how do we get it? Methods and problems of synthesizing data from published reports.

Learning Objectives:
1. Common SBRT fractionation schemes and current evidence for efficacy.
2. Evidence for normal tissue tolerances in hypofractionated treatments.
3. Clinically relevant radiobiological effects at large fraction sizes.


Contact Email: